Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

• Published in: Journal of Pathology and Translational Medicine Vol. 55; no. 3; pp. 181 - 191
• Main Authors: Chang, Sunhee, Shim, Hyo Sup, Kim, Tae Jung, Choi, Yoon-La, Kim, Wan Seop, Shin, Dong Hoon, Kim, Lucia, Park, Heae Surng, Lee, Geon Kook, Lee, Chang Hun
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Pathologists and The Korean Society for Cytopathology 01.05.2021; Korean Society of Pathologists, Korean Society for Cytopathology; The Korean Society of Pathologists and the Korean Society for Cytopathology; Korean Society of Pathologists & the Korean Society for Cytopathology; 대한병리학회
• Subjects: Biomarker; Biomarkers; Carcinoma; carcinoma, non-small-cell lung; Consensus; FDA approval; Kinases; Lung cancer; non-small-cell lung; Pathology; precision medicine; RB1-214; Review; 병리학; Biomarker; Precision medicine; Consensus; Carcinoma, non-small-cell lung
• ISSN: 2383-7837; 2383-7845
• DOI: 10.4132/jptm.2021.03.23

Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.